Patient Gateway

RSS Feed

【HER2 · 实例】PFS 达 29 个月，影像学 PD 后延续用药再获长期疾病稳定：瑞康曲妥珠单抗为 HER2 突变 NSCLC 患者带来持久获益_腾讯新闻

Yago Garitaonaindía: KEYNOTE 867 Results Highlight Toxicity Risks of IO Combined with RT in Early NSCLC

从循证获益到规范实践：EGFR 突变可切除 NSCLC 术后辅助治疗全程管理要点_腾讯新闻

Entrectinib-associated perimyocarditis in ROS1-positive NSCLC: a diagnostic and therapeutic dilemma - a case report

Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC

Predicting response to anti-PD-(L)1 therapies using plasma-derived extracellular vesicles in NSCLC and advanced melanoma: protocol for a prospective multicenter cohort study

Macrophage state in neoadjuvant and perioperative immunotherapy resistance in resectable NSCLC: a critical appraisal of strategies from CSF1R and CD47–SIRPα to CAR-macrophages

HERON-Lung01: HER3-Directed ADC Prolongs Progression-Free Survival in EGFR-Mutated Advanced NSCLC

Osimertinib Plus Savolitinib in EGFR-Mutated NSCLC After Disease Progression

2026 ESMO丨全新一代KRAS G12C抑制剂：Divarasib以III期头对头全面获益，彰显KRAS G12C突变NSCLC后线治疗同类最佳潜力_腾讯新闻